Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome,
Affiliation:
3. 3Centro de Biología Molecular Severo Ochoa (CSIC-UAM), 28049 Madrid, Spain;4. 4Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel;5. 5Immuno-Oncology Laboratory, Paediatric Haematology/Oncology Department, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy;6. 6Department of Ophthalmology, Laboratory of Translational Immunology, University Medical Center, Utrecht University, Utrecht, The Netherlands
Abstract:
Highlights
•HLA-B*51 and ERAP1, but not ERAP2, are risk factors for Behçet's disease.
•The HLA-B*51 peptidome and the effects of ERAP1 and ERAP2 on it are analyzed.
•ERAP1 and ERAP2 alter multiple features of the HLA-B*51 peptidome in distinct ways.
•Both enzymes act independently with complementary and partially redundant functions.